Clinical trials: Hospitalized COVID-19
COVID 19, Rehabilitation
Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients
Conventional in-hospital mobility programs are challenging to deliver to hospitalized infected patients (e.g., COVID-19) due to infection risk to staff, staffing shortages, and potential exposure of other patients.
- Conditions
- COVID 19, Rehabilitation, Inpatient, Hospitalized
- Trial name
- NCT04743401
- Testing
- Tele-exergaming Tablet
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- VA Office of Research and Development
Respiratory Failure, COVID-19
Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization
Acute respiratory distress syndrome (ARDS) is a major complication among patients with severe disease. In a report of 138 patients with COVID-19, 20% developed ARDS at a median of 8 days after the onset of symptoms, with 12.3% of…
- Trial name
- PAPR (NCT04368000)
- Testing
- Intermittent prone positioning instructions, Usual care positioning with no instructions
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
COVID-19 Pneumonia, Pulmonary Embolism
External Validation of the CHOD Risk Scale
Severe COVID-19 is associated with a hypercoagulable state, with a high risk of thrombotic phenomena such as pulmonary thromboembolism (PE).
- Trial name
- CHOD-1 (NCT04889261)
- Where
- Spain
- Volunteers
- 245 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
COVID-19, Influenza
Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza…
- Trial name
- DAN-COMBO (NCT07790523)
- Testing
- mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)
- Where
- 3 sites in Denmark, Spain
- Volunteers
- 410,000 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
SARS-CoV, Nutrition Disorders
Nutritional Assessment of Hospitalized Patients With COVID-19
The nutritional consequences of the infection by the SARS-CoV-2 are as follows: A severe respiratory infection induces an inflammatory syndrome and hypercatabolism, as well as an increase in energy expenditure related to…
- Trial name
- DenutCOVID (NCT04503525)
- Testing
- Nutritional assessment
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Lille Catholic University
Covid19
Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)
Currently, there are few approved treatments for COVID-19, antiretroviral (remdesivir) and corticoids. With about 15% of COVID-19 patients suffering from severe disease health system will be overwhelmed.
- Trial name
- STRUCK (NCT04724629)
- Testing
- Ixekizumab, Aldesleukin, Colchicine
- Where
- 2 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Covid19
Microbial Infection and AMR in Hospitalized Patients With Covid 19
To detect microbial infection and AMR associated with COVID 19 infection. To correlate risk factors of COVID 19 patients with microbial infections and their effects on disease.
- Trial name
- NCT04479982
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
SARS-CoV-2 Infection
Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19
The study investigates whether patients with mild SARS-CoV-2 infection, who stayed at home during their infection and weren't hospitalized, have any persisting sequelae in pulmonary function.
- Trial name
- NCT06318208
- Testing
- lung function testing
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- University of Rostock
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection), Hospitalized Patients
Antibodies Responses to COVID-19 Infection in Hospitalized Patients
1.5. Why this clinical study? The prevalence of seropositivity following SARS-CoV 2 infection might have its own potential benefits in terms of predicting the end of pandemic and the validity of herd immunity.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection), Hospitalized Patients, Laboratory-confirmed SARS-CoV 2 Infection
- Trial name
- No-SARS (NCT04520880)
- Testing
- Testing procedure for Binding antibodies, Neutralizing antibodies
- Where
- Saudi Arabia
- Volunteers
- 158 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
COVID-19
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
ACTT-3 will evaluate the combination of interferon beta-1a and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized.
- Trial name
- NCT04492475
- Testing
- Interferon beta-1a, Remdesivir
- Where
- 64 sites in United States, Japan and 3 more
- Volunteers
- 969 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID, Corona Virus Infection
Predicting Favorable Outcomes in Hospitalized Covid-19 Patients
Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal…
- Conditions
- COVID, Corona Virus Infection, Adverse Event
- Trial name
- NCT04570488
- Testing
- EPIC risk score display
- Where
- United States
- Volunteers
- 1,415 people
- Sponsor
- NYU Langone Health
SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome)
Methylprednisolone in COVID-19 Patients (Methyl19LGH)
In COVID-19 deep airway and alveolar destruction occurred due to inflammatory reaction resulting into severe pneumonia. In COVID-19, lung injury is not only due to viral damage to tissue, but it is also due to immune response…
- Trial name
- Methyl19LGH (NCT04559113)
- Testing
- Methylprednisolone Injectable Product
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Lahore General Hospital
COVID-19
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
- Trial name
- NCT05387369
- Testing
- Paxlovid
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Huashan Hospital